Alzamend Neuro annual meeting results: reverse split approved, Proposal 3 vote adjourned

Alzamend Neuro, Inc.

All eight director nominees elected; Baker Tilly ratified as auditor for FY ending April 30, 2024.
Reverse stock split approved (ratio 1:2 to 1:20, board to set by April 29, 2025).
Proposal 3 (issuance of up to 6M shares to Ault Lending LLC) lacked sufficient votes; meeting adjourned to May 13, 2024 for further voting.
Outstanding shares: 6,849,407 common and 1,220,000 Series B preferred as of March 14, 2024 record date.

item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Alzamend Neuro, Inc. shareholders approved Election of eight director nominees at the 2024-04-30 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal One : The election of eight (8) director nominees named by the Company to hold office until the next annual meeting of stockholders. For Against Abstain Broker Non-Votes Milton C. Ault, III 3,492,046 395,262 14,002 1,698,070 William B. Horne 3,486,146 400,229 14,935 1,698,070 Stephan Jackman 3,714,790 175,219 11,301 1,698,070 Henry C. Nisser 3,698,330 188,030, 14,949 1,698,070 Mark Gustafson 3,514,765 371,660 14,885 1,698,070 Lynne F. McGrath 3,724,920 164,504 11,886 1,698,070 Andrew H. Woo 3,726,599 162,827 11,884 1,698,070 Jeffrey Oram 3,520,732 365,511 15,067 1,698,070

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Alzamend Neuro, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending April 30, 2024 at the 2024-04-30 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal Two : The ratification of Baker Tilly US, LLP, as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024. For Against Abstain Broker Non-Votes 5,114,481 443,299 41,600 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Alzamend Neuro, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to effect a reverse stock split of Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to April 29, 2025 at the 2024-04-30 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal Four : Approval of the amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to April 29, 2025, with the exact ratio to be set at a whole number within this range as determined by the Company’s board of directors in its sole discretion. For Against Abstain Broker Non-Votes 4,476,092 108,096 42,325 0

View on SEC.gov

139 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-24-008007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.